{"title":"锥束ct引导下热消融与视频辅助胸外科治疗非小细胞肺癌：倾向评分匹配分析","authors":"Zhiyuan Zheng, Guoshu Bi, Mengfei Wu, Guangyu Yao, Feihang Wang, Yav Sothea, Jiemin Cheng, Hong Fan, Zhiping Yan, Xiaolin Wang, Lingxiao Liu","doi":"10.4103/jcrt.jcrt_2187_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to compare the safety and effectiveness of cone-beam CT (CBCT)-guided thermal ablation vs video-assisted thoracic surgery (VATS) in patients with stage I-IIIA non-small-cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>A total of 43 NSCLC patients underwent CBCT-guided thermal ablation, and 899 patients received VATS. After 1:1 propensity score matching (PSM), 32 patients were included in each cohort. Overall survival (OS), disease-free survival (DFS), recurrence rates, length of hospital stay, and complications were analyzed.</p><p><strong>Results: </strong>The mean OS was 3.02 ± 1.31 years in the ablation group and 4.79 ± 2.87 years in the VATS group (P = 0.08). The mean DFS was 2.30 ± 1.55 years and 4.34 ± 2.98 years, respectively (P = 0.021). Local and distant recurrence occurred in five (15.6%) and seven (21.9%) patients in the ablation group, and in six (18.8%) and seven (21.9%) patients in the VATS group, with no significant difference in overall recurrence (P = 0.595). The hospital stay was significantly shorter in the ablation group (3.67 ± 2.04 days) than in the VATS group (8.21 ± 3.68 days, P < 0.0001). The incidences of pneumothorax (P = 0.430), infection (P = 0.086), pneumonia (P = 0.554), and fever (P = 0.230) were comparable between groups.</p><p><strong>Conclusion: </strong>CBCT-guided thermal ablation is a safe and effective treatment option for patients with stage I-IIIA NSCLC.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2026-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cone-beam CT-guided thermal ablation vs video-assisted thoracic surgery in treatment of non-small-cell lung cancer: A propensity score matching analysis.\",\"authors\":\"Zhiyuan Zheng, Guoshu Bi, Mengfei Wu, Guangyu Yao, Feihang Wang, Yav Sothea, Jiemin Cheng, Hong Fan, Zhiping Yan, Xiaolin Wang, Lingxiao Liu\",\"doi\":\"10.4103/jcrt.jcrt_2187_25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>This study aimed to compare the safety and effectiveness of cone-beam CT (CBCT)-guided thermal ablation vs video-assisted thoracic surgery (VATS) in patients with stage I-IIIA non-small-cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>A total of 43 NSCLC patients underwent CBCT-guided thermal ablation, and 899 patients received VATS. After 1:1 propensity score matching (PSM), 32 patients were included in each cohort. Overall survival (OS), disease-free survival (DFS), recurrence rates, length of hospital stay, and complications were analyzed.</p><p><strong>Results: </strong>The mean OS was 3.02 ± 1.31 years in the ablation group and 4.79 ± 2.87 years in the VATS group (P = 0.08). The mean DFS was 2.30 ± 1.55 years and 4.34 ± 2.98 years, respectively (P = 0.021). Local and distant recurrence occurred in five (15.6%) and seven (21.9%) patients in the ablation group, and in six (18.8%) and seven (21.9%) patients in the VATS group, with no significant difference in overall recurrence (P = 0.595). The hospital stay was significantly shorter in the ablation group (3.67 ± 2.04 days) than in the VATS group (8.21 ± 3.68 days, P < 0.0001). The incidences of pneumothorax (P = 0.430), infection (P = 0.086), pneumonia (P = 0.554), and fever (P = 0.230) were comparable between groups.</p><p><strong>Conclusion: </strong>CBCT-guided thermal ablation is a safe and effective treatment option for patients with stage I-IIIA NSCLC.</p>\",\"PeriodicalId\":94070,\"journal\":{\"name\":\"Journal of cancer research and therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2026-04-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer research and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrt.jcrt_2187_25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer research and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrt.jcrt_2187_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Cone-beam CT-guided thermal ablation vs video-assisted thoracic surgery in treatment of non-small-cell lung cancer: A propensity score matching analysis.
Aims: This study aimed to compare the safety and effectiveness of cone-beam CT (CBCT)-guided thermal ablation vs video-assisted thoracic surgery (VATS) in patients with stage I-IIIA non-small-cell lung cancer (NSCLC).
Materials and methods: A total of 43 NSCLC patients underwent CBCT-guided thermal ablation, and 899 patients received VATS. After 1:1 propensity score matching (PSM), 32 patients were included in each cohort. Overall survival (OS), disease-free survival (DFS), recurrence rates, length of hospital stay, and complications were analyzed.
Results: The mean OS was 3.02 ± 1.31 years in the ablation group and 4.79 ± 2.87 years in the VATS group (P = 0.08). The mean DFS was 2.30 ± 1.55 years and 4.34 ± 2.98 years, respectively (P = 0.021). Local and distant recurrence occurred in five (15.6%) and seven (21.9%) patients in the ablation group, and in six (18.8%) and seven (21.9%) patients in the VATS group, with no significant difference in overall recurrence (P = 0.595). The hospital stay was significantly shorter in the ablation group (3.67 ± 2.04 days) than in the VATS group (8.21 ± 3.68 days, P < 0.0001). The incidences of pneumothorax (P = 0.430), infection (P = 0.086), pneumonia (P = 0.554), and fever (P = 0.230) were comparable between groups.
Conclusion: CBCT-guided thermal ablation is a safe and effective treatment option for patients with stage I-IIIA NSCLC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
